ES2037499T3 - Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix. - Google Patents

Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.

Info

Publication number
ES2037499T3
ES2037499T3 ES199090107974T ES90107974T ES2037499T3 ES 2037499 T3 ES2037499 T3 ES 2037499T3 ES 199090107974 T ES199090107974 T ES 199090107974T ES 90107974 T ES90107974 T ES 90107974T ES 2037499 T3 ES2037499 T3 ES 2037499T3
Authority
ES
Spain
Prior art keywords
adsorption
procedure
blood coagulation
isolation
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES199090107974T
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Dr. Dipl.-Chem. Moller
Michael Dipl.-Biol. Kraus
Bertram Dr. Eichentopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Application granted granted Critical
Publication of ES2037499T3 publication Critical patent/ES2037499T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES199090107974T 1989-05-05 1990-04-26 Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix. Expired - Lifetime ES2037499T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3914869A DE3914869C1 (cg-RX-API-DMAC10.html) 1989-05-05 1989-05-05

Publications (1)

Publication Number Publication Date
ES2037499T3 true ES2037499T3 (es) 1993-06-16

Family

ID=6380171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES199090107974T Expired - Lifetime ES2037499T3 (es) 1989-05-05 1990-04-26 Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.

Country Status (8)

Country Link
US (1) US5061789A (cg-RX-API-DMAC10.html)
EP (1) EP0396022B1 (cg-RX-API-DMAC10.html)
JP (1) JP2593951B2 (cg-RX-API-DMAC10.html)
AT (1) ATE76751T1 (cg-RX-API-DMAC10.html)
DE (2) DE3914869C1 (cg-RX-API-DMAC10.html)
DK (1) DK0396022T3 (cg-RX-API-DMAC10.html)
ES (1) ES2037499T3 (cg-RX-API-DMAC10.html)
GR (1) GR3005036T3 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
AT395597B (de) * 1991-01-25 1993-01-25 Immuno Ag Reagens zur bestimmung von faktor viii-aktivitaet
BR9205700A (pt) * 1991-03-01 1994-06-28 Rhone Poulenc Rorer Int Aperfeiçoamento em um processo para purificar e preservar fator IX derivado de plasma do sangue humano ou outra fonte, processos para a preparação de uma composição terapêutica, e para estabilizar fator IX, solução aquosa de fator IX parcialmente purificado, composição terapêutica e processo para tratar doença de christmas.
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
DE10045434B4 (de) * 2000-09-14 2005-07-14 Fresenius Hemocare Gmbh Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938741B1 (en) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilization container fill fixture, system and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
EP0041174B1 (en) * 1980-05-27 1985-09-11 Miles Laboratories, Inc. Blood coagulation promoting product and process of preparing same
DE3033932C2 (de) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
DE3826792C1 (cg-RX-API-DMAC10.html) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
ATE76751T1 (de) 1992-06-15
JP2593951B2 (ja) 1997-03-26
DE59000141D1 (de) 1992-07-09
DK0396022T3 (da) 1992-07-20
JPH02306994A (ja) 1990-12-20
EP0396022A1 (de) 1990-11-07
DE3914869C1 (cg-RX-API-DMAC10.html) 1990-08-09
EP0396022B1 (de) 1992-06-03
GR3005036T3 (cg-RX-API-DMAC10.html) 1993-05-24
US5061789A (en) 1991-10-29

Similar Documents

Publication Publication Date Title
ES2037499T3 (es) Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.
Morisawa et al. Cyclic AMP induces maturation of trout sperm axoneme to initiate motility
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
Dragstedt et al. Inhibitory effect of heparin upon histamine release by trypsin, antigen, and proteose.
CO4650143A1 (es) Kit para deteccion de helicobacter pylori
ES2028865T3 (es) Procedimiento mejorado para la preparacion de derivados de macrolidas.
Walaszek et al. Fixation of 5-hydroxytryptamine by brain mitochondria.
Craighead et al. Encephalomyocarditis virus hemagglutination-inhibition test using antigens prepared in HeLa cell cultures
Schuldiner et al. On the mechanism of the energy-dependent quenching of atebrin fluorescence in isolated chloroplasts
Korotkov Effects of Tl+ on ion permeability, membrane potential and respiration of isolated rat liver mitochondria
AR012124A1 (es) Un procedimiento para la preparacion de derivados de tiazolidinadiona, derivados de tiazolidinadiona, su uso y preparados farmaceuticos que contienen a dichos derivados.
BR0113187A (pt) Complexos que contêm perfluoralquila com radicais polares, processo para preparação dos mesmos e seu respectivo uso
ES2075976T3 (es) Derivados de aminoacido y su empleo como agentes antiviricos.
ES465152A1 (es) Procedimiento para la obtencion de derivados del acido %- (aminoacetil)fenoxiacetico.
ES2072492T3 (es) Derivados de acido piridinalqueno- y -aminooxialcano-carboxilico sustituidos por fenilsulfonamida.
AR058361A1 (es) Composiciones lifolizadas de un compuesto de triazolopirimidina
KATZ et al. Effects of local anaesthetics on calcium transport by canine cardiac microsomes (fragmented sarcoplasmic reticulum)
ES2063305T3 (es) Derivados de bifenilo, procedimiento para la preparacion de los mismos e intermedios para los mismos.
ES2146049T3 (es) Benzoilguanidinas, procedimiento para su preparacion y medicamento que las contiene.
ES8604691A1 (es) Perfeccionamientos en los metodos para determinar la actividad de la catepsina b en presencia de otras enzimas proteoliticas
Yang et al. The Mechanism of Propofol on Non-Small Cell Lung Cancer (NSCLC) through Modulating Mesenchymal Transition (EMT)
ES8302732A1 (es) Procedimiento para la obtencion de una 4-aminoimidazolo(4,5-c,7)-rifamicina sv o s.
GB919428A (en) Process for decolorising and/or stabilizing against discoloration aromatic compounds
AR043171A1 (es) Sal de cetilpiridinio de un agente antiinflamatorio, composiciones farmaceuticas que la contienen y un procedimiento para la preparacion de la sal.
Tchaperoff Preliminary Notes on the Effect of Roentgen Rays on Sulfonamides in Vitro